Physician profile
Bakhtiar Ali
NPI 1396767695
$5,859.07
in general payments reported to CMS, 2019-2025
31 companies · $480 in 2025
The $480 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,533 · 2020: $438 · 2021: $628 · 2022: $1,214 · 2023: $964 · 2024: $601 · 2025: $480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,046.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,046.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,025.09 | 2019-2024 | Watchman Flx, Ranger, Jetstream Sc |
| Janssen Pharmaceuticals, INC | $974.06 | 2019-2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $839.50 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $595.34 | 2019-2024 | Farxiga |
| Merck Sharp & Dohme LLC | $345.65 | 2021-2025 | Verquvo, Capvaxive |
| Novartis Pharmaceuticals Corporation | $301.87 | 2019-2023 | |
| Amgen INC. | $239.55 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $197.35 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $143.76 | 2019-2024 | Evkeeza |
| E.R. Squibb & Sons, L.L.C. | $133.30 | 2019-2023 | Eliquis |
| Baxter Healthcare | $126.44 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Astellas Pharma US INC | $121.76 | 2019-2021 | |
| Abbott Laboratories | $119.15 | 2021-2024 | Mitraclip |
| Philips North America LLC | $96.42 | 2020-2023 | |
| Alnylam Pharmaceuticals INC. | $77.08 | 2021-2025 | Amvuttra |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $76.54 | 2024 | Inspire |
| Abiomed | $55.19 | 2019-2024 | Impella |
| Esperion Therapeutics, INC. | $47.15 | 2025 | Nexletol |
| Lundbeck LLC | $45.18 | 2019 | |
| Amarin Pharma, INC. | $38.62 | 2019 | |
| Novo Nordisk INC | $38.08 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $34.55 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.97 | 2019-2023 | Jardiance |
| Bridgebio Pharma, INC. | $24.21 | 2025 | Attruby |
| Cordis US Corp. | $23.19 | 2025 | Mynx Control |
| Cardiva Medical, INC. | $20.96 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $20.60 | 2025 | Opsumit |
| Angiodynamics, INC. | $18.87 | 2022 | |
| Catheter Precision, INC. Fka Ra Medical Systems, INC. | $16.83 | 2019 | |
| Chiesi USA, INC. | $16.72 | 2019 | |
| Kestra Medical Technology Services, INC. | $15.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bakhtiar Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.